Previous 10 | Next 10 |
(NewsDirect) From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth contro...
--News Direct-- From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth con...
--News Direct-- Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/ View original content to download multimedia: https://newsdirect.c...
Agile Therapeutics ( NASDAQ: AGRX ) said on Oct. 7 that it appointed Amy Welsh as chief commercial officer, effective Nov. 1, as part of a reorganization of its leadership team to to promote birth control patch Twirla (levonorgestrel and ethinyl estradiol). ...
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla ® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- ...
The following slide deck was published by Agile Therapeutics, Inc. in conjunction with this event. For further details see: Agile Therapeutics (AGRX) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow
PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24 th Annual Glob...
Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript
Agile Therapeutics, Inc. (AGRX) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright ...
Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 GAAP EPS of -$2.71 beats by $0.99 . Revenue of $2.1M (+75.0% Y/Y) beats by $0.12M . “Our goals as a company are to grow our Twirla brand and become cash flow positive. We believe we took important ste...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...